FDA Closes Investigation of 14-State MOGO Moringa Salmonella Outbreak
The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention have concluded their investigation into a multistate Salmonella Typhimurium outbreak linked to MOGO-brand moringa powder capsules distributed by MOGO Moringa LLC of St. Louis, Missouri.
As of July 17, 2026, the CDC has declared the outbreak over. The investigation identified 34 illnesses across 14 states, including 11 hospitalizations, with no deaths reported. Illnesses occurred between August 27, 2025, and June 21, 2026. The investigation also identified one case in which an infant became ill after the child’s mother consumed the moringa capsules while breastfeeding.
FDA and its state partners conducted traceback investigations, facility inspections, and laboratory testing to determine the source of the contamination. Traceback records showed that MOGO Moringa LLC sourced all of its moringa leaf powder from India. FDA investigators inspected both the ingredient supplier and the product manufacturer, issuing inspectional observations to both facilities at the conclusion of the inspections.
Laboratory testing by health departments in Washington, Tennessee, and Florida confirmed the outbreak strain of Salmonella in opened containers of MOGO-brand moringa capsules collected from consumers.
Although the outbreak investigation has ended, FDA announced it has increased screening of imported moringa powder from India for Salmonella to help prevent future contaminated products from entering the U.S. market. Because the recalled capsules have a long shelf life, consumers are advised to check their homes and discard any affected products.
This investigation is the latest in a series of FDA actions involving Salmonella-contaminated moringa products, highlighting ongoing concerns about the safety of imported botanical ingredients and the complexity of global dietary supplement supply chains.
